Childhood Acute Myeloid Leukemia

被引:0
作者
Jeffrey E. Rubnitz
机构
[1] St. Jude Children’s Research Hospital,Department of Oncology
来源
Current Treatment Options in Oncology | 2008年 / 9卷
关键词
Acute Myeloid Leukemia; Minimal Residual Disease; Acute Myeloid Leukemia Patient; Gemtuzumab Ozogamicin; Clofarabine;
D O I
暂无
中图分类号
学科分类号
摘要
Despite the use of intensive chemotherapy and hematopoietic stem cell transplantation, approximately one-third of children with acute myeloid leukemia (AML) still suffer relapse of their disease. It is unlikely that improvements in outcome can be achieved by further intensification of conventional chemotherapy. Instead, advances in the treatment of children with AML will require a greater understanding of the biology of the disease, with particular attention to the genetic abnormalities underlying leukemogenesis and drug resistance. Future clinical trials should include refined risk-directed therapy based on the genetics of the leukemic blasts and the patient’s response to therapy. More important, we must develop alternative treatment approaches, such as agents that target specific leukemia-associated abnormalities and agents that selectively eradicate leukemic stem cells.
引用
收藏
页码:95 / 105
页数:10
相关论文
共 173 条
[51]  
Diekamp S(2007)Exploiting signal transduction pathways in acute myelogenous leukemia Curr Treat Options Oncol 8 265-276
[52]  
Langebrake C(2007)Novel therapies targeting the apoptosis pathway for the treatment of acute myeloid leukemia Curr Treat Options Oncol 8 277-286
[53]  
Grimwade D(2004)Determinants of antileukemia effects of allogeneic NK cells J Immunol 172 644-650
[54]  
Walker H(2002)Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 2097-2100
[55]  
Oliver F(2003)Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors Blood 102 814-819
[56]  
Appelbaum F(2005)Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes Blood 105 4878-4884
[57]  
Kopecky KJ(2007)Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT Blood 109 5058-5061
[58]  
Tallman M(2007)Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: Challenging its predictive value Blood 110 433-440
[59]  
Rubnitz JE(2005)Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors J␣Immunol 174 6540-6545
[60]  
Raimondi SC(2005)Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer Blood 105 3051-3057